Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial -

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
RCT (n=270) conducted in China found that utidelone, a genetically engineered epothilone analogue, in combination with capecitabine, improved median progression-free survival vs capecitabine alone (8.44 vs. 4.27 months, HR 0.46, 95% CI 0.36–0.59; p<0.0001).
UKMi comment
A commentary notes that although encouraging, mature overall survival data are needed before making any decision for regulatory approval of utidelone. It acknowledges that new treatments such as utidelone, with new mechanisms of action and non-overlapping toxicity profiles are needed, particularly for patients with refractory disease.
Related links: Comment